Pastilles overtake oil among 18-44 age group as SAS-B approvals near 2024 total by Steve Jones October 1, 2025October 1, 2025 Pastilles have overtaken oil as the second most prescribed dosage form among the 18-44 age demographic, […]
SAS-B approvals slow in August but pastille scripts continue to rise by Steve Jones September 3, 2025February 21, 2026
July SAS-B approvals edge higher as pastilles share rises beyond 20% by Adam Sheldon August 5, 2025August 6, 2025
SAS-B approvals hit all-time high in April as Tasmania spikes again by Steve Jones May 2, 2025May 2, 2025
News in brief: Tilray launches pastilles; InhaleRx progresses panic disorder trial; NSW calls for hemp plan feedback; BS3 makes key hire by Steve Jones and Martin Lane April 23, 2025April 23, 2025
SAS-B approvals hit second highest on record as Tassie shows surprise growth by Steve Jones April 2, 2025April 2, 2025
Althea blames medical sales decline on TGA ‘falling asleep at the wheel’ amid ‘crazy’ antics of competitors by Steve Jones March 21, 2025March 26, 2025
Two-month total of SAS-B approvals up 47% on 2024, TGA data shows by Steve Jones March 4, 2025April 1, 2025
Pastilles drive Bioxyne to first-half profit after revenue climbs 171% by Steve Jones March 3, 2025March 3, 2025
Growth of pastilles accelerates as SAS approvals get off to strong start in 2025 by Steve Jones February 17, 2025February 17, 2025
